{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-135024","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.386876+00:00","generated_at":"2026-06-15T22:33:54.808526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AlloVir reports Q1 net loss $41.2M; Phase 3 posoleucel trials on track for 2024","bullets":["Net loss of $41.2M ($0.44/share) vs $43.9M ($0.69/share) in Q1 2022.","Cash, cash equivalents and short-term investments were $202.6M as of March 31, 2023.","R&D expenses $30.7M, G&A $12.5M; FY 2023 operating expense guidance $150M-$170M excl. non-cash.","Three Phase 3 registrational trials of posoleucel in allo-HCT patients continue enrolling; data readouts expected in 2024.","Positive Phase 2 data for posoleucel in BK viremia in kidney transplant recipients to be presented at ATC 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-135024","json":"https://secwatch.observer/filing/0001193125-23-135024.json","markdown":"https://secwatch.observer/filing/0001193125-23-135024.md","text":"https://secwatch.observer/filing/0001193125-23-135024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/0001193125-23-135024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/d277750d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:33:54.808526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"863c2e7f202e9eb175aae2e79594f1c94e9fd12e","claim":"Kalaris Therapeutics, Inc. updated its fiscal year 2023 guidance (initiated).","evidence_excerpt":"For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash expenses.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/0001193125-23-135024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"a106e43678b596ce99e1c7fbc5974f8af2558e5a","claim":"Kalaris Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $41.2 million, EPS $0.44 per share.","evidence_excerpt":"For the quarter ended March 31, 2023, net loss was $41.2 million or $0.44 per share compared with a net loss of $43.9 million or $0.69 per share for the quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/0001193125-23-135024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$41.2 million"},{"label":"EPS","value":"$0.44 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}